Raymond James Financial’s Prothena PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$95.9K Buy
11,447
+1
+0% +$9 ﹤0.01% 5224
2026
Q2
$112K Sell
11,446
-438
-4% -$4.32K ﹤0.01% 5159
2026
Q1
$116K Sell
11,884
-4,599
-28% -$42.1K ﹤0.01% 5006
2025
Q4
$157K Sell
16,483
-5,549
-25% -$56.5K ﹤0.01% 4845
2025
Q3
$215K Buy
22,032
+8,536
+63% +$65.6K ﹤0.01% 4594
2025
Q2
$81.9K Buy
13,496
+1,009
+8% +$7.57K ﹤0.01% 4963
2025
Q1
$155K Sell
12,487
-624
-5% -$8.82K ﹤0.01% 4476
2024
Q4
$182K Buy
+13,111
New +$207K ﹤0.01% 4425

Other funds holding PRTA

Raymond James Financial's PRTA Position: Q3 2026 in Review

Raymond James Financial increased its Prothena (PRTA) stake by 0.01% in Q3 2026, buying an estimated $9 and bringing the position to 11,447 shares worth $95.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5224.

Raymond James Financial first reported a position in PRTA in Q4 2024 and has held it in 8 quarters since. The position peaked at $215K in Q3 2025. 180 funds tracked by Wall St. Rank hold PRTA as of Q3 2026.

  • Raymond James Financial held 11,447 shares of Prothena worth $95.9K as of Q3 2026.
  • Raymond James Financial bought 1 Prothena share in Q3 2026, an estimated $9.
  • Prothena made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5224 holding.
  • Raymond James Financial first reported a position in Prothena in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Prothena position peaked at $215K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Prothena as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.